[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.216.242. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
February 3, 1999

Coronary Events With Lipid-Lowering Therapy: The AFCAPS/TexCAPS Trial

Author Affiliations
 

Margaret A.WinkerMD, Deputy EditorIndividualAuthorPhil B.FontanarosaMD, Interim Co-EditorIndividualAuthor

JAMA. 1999;281(5):414-419. doi:10-1001/pubs.JAMA-ISSN-0098-7484-281-5-jbk0203

To the Editor: The results of AFCAPS/TexCAPS1 are impressive in terms of primary vascular disease prevention. The significant (P=.04) reduction in melanoma cases (14 vs 27) in the lovastatin group is also of interest because this drug inhibits melanoma cell growth in animal models.24 The mechanism involved is not clearly defined. We could not identify any publications involving other statins in similar models of melanoma. However, statins (eg, simvastatin) have been suggested to potentiate the effect of antiblastic drugs on tumor growth.5

First Page Preview View Large
First page PDF preview
First page PDF preview
×